Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT06759077
PHASE3
Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life
Sponsor: Al-Azhar University
View on ClinicalTrials.gov
Summary
If this study has a cardio protective effect it will affect the mortality and morbidity of advanced CKD patients and improve their quality of life
Official title: Potential Beneficial Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
126
Start Date
2024-12-28
Completion Date
2025-12-28
Last Updated
2025-01-08
Healthy Volunteers
No
Conditions
Interventions
DRUG
Dapagliflozin (DAPA)
adult patients with advanced CKD who will take SGL2I(DAPAGLIFLOZINE at a dose (10 mg/day) orally for 6months
Locations (1)
faculty of pharmacy (girls )ALAzhar university
Cairo, Egypt